Ibrutinib/rituximab versus placebo/rituximab: A randomized, phase 3 trial in Waldenström's macroglobulinemia (iNNOVATE) Meeting Abstract
| Authors: | Palomba, M. L.; Dimopoulos, M. A.; Tedeschi, A.; Trotman, J.; García-Sanz, R.; MacDonald, D.; Leblond, V.; Mahe, B.; Herbaux, C.; Tam, C.; Matous, J. V.; Shustik, C.; Kastritis, E.; Treon, S. P.; Li, J.; Salman, Z.; Graef, T.; Buske, C. |
| Abstract Title: | Ibrutinib/rituximab versus placebo/rituximab: A randomized, phase 3 trial in Waldenström's macroglobulinemia (iNNOVATE) |
| Meeting Title: | 6th Annual Meeting of the Society of Hematologic Oncology (SOHO 2018) |
| Keywords: | rituximab; combination therapy; ibrutinib; waldenstrom's macroglobulinemia |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 18 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Sep 12-15 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2018-09-01 |
| Start Page: | S283 |
| Language: | English |
| ACCESSION: | WOS:000444343400265 |
| DOI: | 10.1016/j.clml.2018.07.217 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: NHL-191 -- Source: Wos |
